Dr Kara Brightman Johnson Wegermann, MD | |
Clinic 2b/2c 40 Duke Medicine Circle, Durham, NC 27710-4699 | |
(919) 684-1817 | |
Not Available |
Full Name | Dr Kara Brightman Johnson Wegermann |
---|---|
Gender | Female |
Speciality | Gastroenterology |
Experience | 10 Years |
Location | Clinic 2b/2c 40 Duke Medicine Circle, Durham, North Carolina |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1447678966 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RG0100X | Internal Medicine - Gastroenterology | 2018-00921 (North Carolina) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Duke University Hospital | Durham, NC | Hospital |
Duke Regional Hospital | Durham, NC | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Duke Health Integrated Practice Inc | 8325412737 | 2551 |
News Archive
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the attention-deficit/hyperactivity disorder (ADHD) drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan will fluctuate modestly over the next decade, decreasing from $5 billion in 2009 to a trough in 2013 before climbing to $4.1 billion in 2019.
A clinical study conducted by researchers of the Faculty of Medicine and Health Sciences of the UB shows that control of type 2 diabetes improves notably when the patient takes a special care of the dental hygiene.
Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, today announced it has completed the acquisition of an active pharmaceutical ingredient (API) manufacturing facility and an associated research and development (R&D) facility from Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, for approximately $218 million, after settling prior advances of approximately $30 million.
› Verified 9 days ago
Entity Name | Private Diagnostic Clinic Pllc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1457389033 PECOS PAC ID: 1355254368 Enrollment ID: O20031204000577 |
News Archive
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the attention-deficit/hyperactivity disorder (ADHD) drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan will fluctuate modestly over the next decade, decreasing from $5 billion in 2009 to a trough in 2013 before climbing to $4.1 billion in 2019.
A clinical study conducted by researchers of the Faculty of Medicine and Health Sciences of the UB shows that control of type 2 diabetes improves notably when the patient takes a special care of the dental hygiene.
Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, today announced it has completed the acquisition of an active pharmaceutical ingredient (API) manufacturing facility and an associated research and development (R&D) facility from Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, for approximately $218 million, after settling prior advances of approximately $30 million.
› Verified 9 days ago
Entity Name | Duke Health Integrated Practice Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1205553369 PECOS PAC ID: 8325412737 Enrollment ID: O20230327002247 |
News Archive
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the attention-deficit/hyperactivity disorder (ADHD) drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan will fluctuate modestly over the next decade, decreasing from $5 billion in 2009 to a trough in 2013 before climbing to $4.1 billion in 2019.
A clinical study conducted by researchers of the Faculty of Medicine and Health Sciences of the UB shows that control of type 2 diabetes improves notably when the patient takes a special care of the dental hygiene.
Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, today announced it has completed the acquisition of an active pharmaceutical ingredient (API) manufacturing facility and an associated research and development (R&D) facility from Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, for approximately $218 million, after settling prior advances of approximately $30 million.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Kara Brightman Johnson Wegermann, MD Dumc 3923 40 Duke Medicine Circle, Durham, NC 27710-4699 Ph: (919) 684-1817 | Dr Kara Brightman Johnson Wegermann, MD Clinic 2b/2c 40 Duke Medicine Circle, Durham, NC 27710-4699 Ph: (919) 684-1817 |
News Archive
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the attention-deficit/hyperactivity disorder (ADHD) drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan will fluctuate modestly over the next decade, decreasing from $5 billion in 2009 to a trough in 2013 before climbing to $4.1 billion in 2019.
A clinical study conducted by researchers of the Faculty of Medicine and Health Sciences of the UB shows that control of type 2 diabetes improves notably when the patient takes a special care of the dental hygiene.
Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, today announced it has completed the acquisition of an active pharmaceutical ingredient (API) manufacturing facility and an associated research and development (R&D) facility from Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, for approximately $218 million, after settling prior advances of approximately $30 million.
› Verified 9 days ago
Dr. Stephen John Greene, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2301 Erwin Rd # Dumc3845, Durham, NC 27705 Phone: 919-684-8111 | |
Dr. Jacob Paul Feigal, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: Duke University Hospital Gme, Box 3951, Durham, NC 27710 Phone: 919-684-8111 | |
Dr. David Keith Bright, MD, PHARM D Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 4205 Ben Franklin Blvd, Durham, NC 27704 Phone: 919-477-6900 Fax: 919-477-5081 | |
Yuri Anthony Fesko, MD Gastroenterology Medicare: Medicare Enrolled Practice Location: 4101 N Roxboro St, Durham, NC 27704 Phone: 919-684-8111 | |
Mary E Klotman, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 40 Duke Medicine Cir, Durham, NC 27710 Phone: 919-684-8111 | |
Jonathan Paul Piccini Sr., M.D., M.H.S. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 40 Duke Medicine Cir, Durham, NC 27710 Phone: 919-684-8111 | |
Dr. Deborah Anne Fisher, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 508 Fulton St, Durham, NC 27705 Phone: 919-286-6945 |